Sensus Healthcare (NASDAQ:SRTS) Shares Down 0.3% – Should You Sell?

Sensus Healthcare, Inc. (NASDAQ:SRTS)’s share price dropped 0.3% during trading on Monday . The stock traded as low as $3.00 and last traded at $3.02. Approximately 30,645 shares traded hands during mid-day trading, an increase of 39% from the average daily volume of 22,123 shares. The stock had previously closed at $3.03.

Wall Street Analyst Weigh In

SRTS has been the topic of several research reports. Weiss Ratings restated a “sell (d)” rating on shares of Sensus Healthcare in a report on Friday, July 17th. Wall Street Zen lowered shares of Sensus Healthcare from a “sell” rating to a “strong sell” rating in a report on Saturday, May 9th. Finally, Citigroup reiterated a “buy” rating on shares of Sensus Healthcare in a research report on Friday, May 8th. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $6.88.

Sensus Healthcare Price Performance

The firm has a market capitalization of $49.72 million, a price-to-earnings ratio of -6.43 and a beta of 1.09. The stock has a fifty day moving average of $2.97 and a two-hundred day moving average of $3.83.

Sensus Healthcare (NASDAQ:SRTS) last announced its earnings results on Thursday, May 7th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.04). Sensus Healthcare had a negative return on equity of 15.79% and a negative net margin of 34.50%.The company had revenue of $3.39 million for the quarter, compared to the consensus estimate of $5.32 million.

Hedge Funds Weigh In On Sensus Healthcare

Hedge funds and other institutional investors have recently made changes to their positions in the stock. XTX Topco Ltd acquired a new stake in Sensus Healthcare in the fourth quarter valued at approximately $77,000. Jane Street Group LLC acquired a new position in shares of Sensus Healthcare during the fourth quarter worth approximately $79,000. Ingalls & Snyder LLC acquired a new position in shares of Sensus Healthcare during the fourth quarter worth approximately $219,000. State Street Corp lifted its holdings in shares of Sensus Healthcare by 5.2% in the 4th quarter. State Street Corp now owns 69,252 shares of the company’s stock worth $276,000 after purchasing an additional 3,400 shares in the last quarter. Finally, North Star Investment Management Corp. bought a new position in shares of Sensus Healthcare in the 1st quarter worth $500,000. 25.30% of the stock is owned by institutional investors and hedge funds.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.